• Roivant flagged upcoming topline results from its Phase 2 PHocus study of mosliciguat in pulmonary hypertension tied to interstitial lung disease.
• Results have not been presented yet; the readout is scheduled for the ERS Congress 2026 on Sep. 8, 2026.
• The update sets a near-term catalyst for the inhaled drug candidate, a key program in Roivant’s pulmonary hypertension pipeline.
• An investor call is set for 8:00 a.m. ET the same day to discuss the topline data.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609060100PRIMZONEFULLFEED9822036) on September 06, 2026, and is solely responsible for the information contained therein.